GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intervacc AB (OSTO:IVACC) » Definitions » Debt-to-Equity

Intervacc AB (OSTO:IVACC) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Intervacc AB Debt-to-Equity?

Intervacc AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Intervacc AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Intervacc AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr220.54 Mil. Intervacc AB's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Intervacc AB's Debt-to-Equity or its related term are showing as below:

During the past 10 years, the highest Debt-to-Equity Ratio of Intervacc AB was 0.18. The lowest was 0.00. And the median was 0.00.

OSTO:IVACC's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

Intervacc AB Debt-to-Equity Historical Data

The historical data trend for Intervacc AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intervacc AB Debt-to-Equity Chart

Intervacc AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Intervacc AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intervacc AB's Debt-to-Equity

For the Biotechnology subindustry, Intervacc AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intervacc AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intervacc AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Intervacc AB's Debt-to-Equity falls into.



Intervacc AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Intervacc AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Intervacc AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intervacc AB  (OSTO:IVACC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Intervacc AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Intervacc AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Intervacc AB (OSTO:IVACC) Business Description

Traded in Other Exchanges
Address
Vastertorpsvagen 135, Hagersten, Stockholm, SWE, S-129 44
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.

Intervacc AB (OSTO:IVACC) Headlines

No Headlines